Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials.
Antiviral therapy
Cirrhosis
Hepatitis B e Antigen
Hepatitis B surface antigen
Hepatitis B virus DNA
Hepatocellular carcinoma
Immunotherapy
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
entrez:
4
7
2019
pubmed:
4
7
2019
medline:
9
4
2020
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) infection is the most common chronic viral infection worldwide and remains a significant global health problem. Chronic HBV infection can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Outcome of chronic HBV infections depends on the host, virus, and environmental factors. Although effective prophylactic vaccines and antiviral therapies exist, curative treatment is not yet available. Intense research into a cure for HBV is ongoing and proposed definitions of cure and endpoints for clinical trials evaluating "curative" therapy are discussed.
Identifiants
pubmed: 31266616
pii: S1089-3261(19)30015-7
doi: 10.1016/j.cld.2019.04.002
pii:
doi:
Substances chimiques
Hepatitis B e Antigens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-416Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.